Reports received by FDA, by month

October 2010: adverse event reports received by FDA

39,544 drug reports (FAERS) and 32,961 device reports (MAUDE).

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

39,544
drug reports received: 28,431 a year earlier; 37,302
monthly average, preceding 12 months: 6% against the average; 32,961
device reports received: 18,232 a year earlier

FDA received 39,544 drug adverse event reports in October 2010, against 28,431 in the same month a year earlier and a monthly average of 37,302 over the preceding 12 months. The MAUDE device database received 32,961 reports that month (18,232 a year earlier).

The drugs listed most often as suspect products were Advair Diskus 100/50 (2,354), Tysabri (1,980) and Symbicort (1,277), and the reactions recorded most often were drug ineffective (2,401), dyspnoea (1,816) and death (1,653).

Relative to their own average over the preceding 12 months, the drugs whose report count rose most were Advair Diskus 100/50 (29.2× its average), Symbicort (26.5× its average) and Advil pm (19.8× its average). A jump in one month usually reflects a batch of reports from a manufacturer, a publicised event or a new product, not a change in what happens to patients.

Drug reports by month, three years to October 2010

Drugs listed most often as suspect products

Drug	Reports	Share of the month
Advair Diskus 100/50	2,354	6%
Tysabri	1,980	5%
Symbicort	1,277	3.2%
Lipitor	1,192	3%
Prempro	984	2.5%
Avandia	943	2.4%
Premarin	842	2.1%
Avonex	718	1.8%
Provera	675	1.7%
Remicade	619	1.6%
Dianeal	592	1.5%
Lupron Depot	522	1.3%
Exjade	439	1.1%
Humira	435	1.1%
Lyrica	419	1.1%

FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Largest rises against their own average

Drug	Reports this month	Times its 12-month average
Advair Diskus 100/50	2,354	29.2×
Symbicort	1,277	26.5×
Advil pm	214	19.8×
Lupron Depot	522	8×
Ampyra	141	6.3×
Avapro	112	5.6×
Pantoprazole sodium	207	5.6×
Venlafaxine hydrochloride	248	5.2×

Drugs with at least 50 reports in the month and an average of at least 10 a month over the preceding year. A rise usually reflects a batch of manufacturer reports, a publicised event or a new product.

Reactions recorded most often

MedDRA term	Reports	Share of the month
Drug ineffectivethe medicine did not work as expected	2,401	6.1%
Dyspnoeashortness of breath	1,816	4.6%
Deaththe patient died; cause not stated by this term	1,653	4.2%
Nauseafeeling sick	1,481	3.7%
Fatiguetiredness	1,389	3.5%
Headachehead pain	1,358	3.4%
Dizzinesslight-headedness or unsteadiness	1,182	3%
Vomitingbeing sick	1,028	2.6%
Painpain, site not specified	1,012	2.6%
Breast cancerbreast cancer	956	2.4%
Product quality issuea problem with the product itself	939	2.4%
Diarrhoealoose or frequent stools	922	2.3%
Malaisegeneral feeling of being unwell	897	2.3%
Astheniaweakness or lack of energy	874	2.2%
Myocardial infarctionheart attack	872	2.2%

Devices named most often

Brand	Reports	Share of device reports
Capsurefix Novus	764	2.3%
Endotak Reliance	687	2.1%
Sprint Quattro Secure	461	1.4%
Ot Ping Meter	419	1.3%
Vitality 2	390	1.2%
Animas Insulin Infusion Pump	318	1%
Teligen	315	1%
Contak Renewal	311	0.9%
Ot Ultralink Meter	293	0.9%
Greenlight Addstat	287	0.9%

Questions about October 2010

How many adverse event reports did FDA receive in October 2010?

39,544 drug reports are in the openFDA FAERS release of 28 Sep 2026, and 32,961 device reports in the MAUDE release of 28 Sep 2026. The same month a year earlier has 28,431 drug reports.

Which drugs were listed most often?

Advair Diskus 100/50 (2,354), Tysabri (1,980), Symbicort (1,277), Lipitor (1,192) and Prempro (984).

Which reactions were recorded most often?

drug ineffective (2,401), dyspnoea (1,816), death (1,653), nausea (1,481) and fatigue (1,389).

Can the count for a month still change?

Yes. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Older months change little.

Does a busy month mean something happened that month?

Not by itself. The date is when FDA received the report, not when the event occurred, and volume follows manufacturer batches, product launches and publicity. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.